Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Don't want to spend a fortune and break the bank on investing in growth stocks? If you're looking for cheap growth stocks to ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...

Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.